Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains-Reference-Cited by-同舟云学术

Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains

Published:2010-11-18 Issue:1 Volume:26 Page:27-36
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov. Disord.

Author:

Bartus Raymond T.,Herzog Christopher D.,Chu Yaping,Wilson Alistair,Brown Lamar,Siffert Joao,Johnson Eugene M.,Olanow C. Warren,Mufson Elliott J.,Kordower Jeffrey H.

Funder

Michael J. Fox Foundation for Parkinson's Research

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.23442/fullpdf

Reference37 articles.

1. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons;Akerud;J Neurochem,1999

2. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons;Horger;J Neurosci,1998

3. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease;Kordower;Science,2000

4. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys;Kordower;Ann Neurol,2006

5. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease;Kordower;Ann Neurol,1999

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurosurgical gene therapy for central nervous system diseases;Neurotherapeutics;2024-07

2. Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature;Biomedicines;2024-02-29

3. Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells;Advanced Healthcare Materials;2024-02-11

4. Oxidative stress induced by sustained supraphysiological intrastriatal GDNF delivery is prevented by dose regulation;Molecular Therapy - Methods & Clinical Development;2023-12

5. Post‐Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery;Movement Disorders;2023-08-06